Is ABEO or TRAX more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Abeona Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Abeona Therapeutics N/A -41.69% -30.36% First Tracks Biotherapeutics N/A N/A N/A

Is ABEO or REPL more profitable?

Abeona Therapeutics' return on equity of -41.69% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Abeona Therapeutics N/A -41.69% -30.36% Replimune Group N/A -159.32% -90.84%

Does the media favor ABEO or REPL?

In the previous week, Abeona Therapeutics and Abeona Therapeutics both had 15 articles in the media. Replimune Group's average media sentiment score of 0.32 beat Abeona Therapeutics' score of 0.29 indicating that Replimune Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Replimune Group 3 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ABEO or IMTX?

In the previous week, Abeona Therapeutics had 11 more articles in the media than Immatics. MarketBeat recorded 15 mentions for Abeona Therapeutics and 4 mentions for Immatics. Abeona Therapeutics' average media sentiment score of 0.29 beat Immatics' score of 0.02 indicating that Abeona Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immatics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, ABEO or VOR?

Abeona Therapeutics has higher revenue and earnings than Vor Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abeona Therapeutics $5.82M 49.42 $71.18M -$1.09 N/A Vor Biopharma N/A N/A N/A N/A N/A

Is ABEO or VOR more profitable?

Vor Biopharma's return on equity of 0.00% beat Abeona Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Abeona Therapeutics N/A -41.69% -30.36% Vor Biopharma N/A N/A N/A

Does the media refer more to ABEO or VOR?

In the previous week, Abeona Therapeutics had 7 more articles in the media than Vor Biopharma. MarketBeat recorded 15 mentions for Abeona Therapeutics and 8 mentions for Vor Biopharma. Abeona Therapeutics' average media sentiment score of 0.29 beat Vor Biopharma's score of 0.21 indicating that Abeona Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vor Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MNKD or ABEO?

In the previous week, Abeona Therapeutics had 7 more articles in the media than MannKind. MarketBeat recorded 15 mentions for Abeona Therapeutics and 8 mentions for MannKind. MannKind's average media sentiment score of 0.41 beat Abeona Therapeutics' score of 0.29 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Abeona Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Abeona Therapeutics (ABEO) Competitors

$5.11 +0.08 (+1.59%)

Closing price 04:00 PM Eastern

Extended Trading

$5.11 0.00 (-0.10%)

As of 07:30 PM Eastern

Compare

ABEO vs. TRAX, REPL, IMTX, VOR, and MNKD

Should you buy Abeona Therapeutics stock or one of its competitors? Abeona Therapeutics's main competitors and comparable companies include First Tracks Biotherapeutics (TRAX), Replimune Group (REPL), Immatics (IMTX), Vor Biopharma (VOR), and MannKind (MNKD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Abeona Therapeutics compare to First Tracks Biotherapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, Abeona Therapeutics had 9 more articles in the media than First Tracks Biotherapeutics. MarketBeat recorded 15 mentions for Abeona Therapeutics and 6 mentions for First Tracks Biotherapeutics. First Tracks Biotherapeutics' average media sentiment score of 0.58 beat Abeona Therapeutics' score of 0.29 indicating that First Tracks Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
First Tracks Biotherapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

First Tracks Biotherapeutics' return on equity of 0.00% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-41.69%	-30.36%
First Tracks Biotherapeutics	N/A	N/A	N/A

Abeona Therapeutics currently has a consensus target price of $21.00, indicating a potential upside of 317.50%. First Tracks Biotherapeutics has a consensus target price of $65.17, indicating a potential upside of 95.81%. Given Abeona Therapeutics' higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than First Tracks Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

80.6% of Abeona Therapeutics shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Abeona Therapeutics has higher revenue and earnings than First Tracks Biotherapeutics. First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	49.42	$71.18M	-$1.09	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A

Summary

Abeona Therapeutics beats First Tracks Biotherapeutics on 7 of the 12 factors compared between the two stocks.

How does Abeona Therapeutics compare to Replimune Group?

Abeona Therapeutics (NASDAQ:ABEO) and Replimune Group (NASDAQ:REPL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Abeona Therapeutics has higher revenue and earnings than Replimune Group. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	49.42	$71.18M	-$1.09	N/A
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A

Abeona Therapeutics presently has a consensus price target of $21.00, suggesting a potential upside of 317.50%. Replimune Group has a consensus price target of $12.00, suggesting a potential downside of 8.19%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Abeona Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Abeona Therapeutics and Abeona Therapeutics both had 15 articles in the media. Replimune Group's average media sentiment score of 0.32 beat Abeona Therapeutics' score of 0.29 indicating that Replimune Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Replimune Group	3 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abeona Therapeutics has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

Abeona Therapeutics' return on equity of -41.69% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-41.69%	-30.36%
Replimune Group	N/A	-159.32%	-90.84%

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by insiders. Comparatively, 5.4% of Replimune Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Abeona Therapeutics beats Replimune Group on 9 of the 14 factors compared between the two stocks.

How does Abeona Therapeutics compare to Immatics?

Abeona Therapeutics (NASDAQ:ABEO) and Immatics (NASDAQ:IMTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Abeona Therapeutics currently has a consensus target price of $21.00, indicating a potential upside of 317.50%. Immatics has a consensus target price of $20.60, indicating a potential upside of 171.41%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Abeona Therapeutics is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Abeona Therapeutics has higher earnings, but lower revenue than Immatics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	49.42	$71.18M	-$1.09	N/A
Immatics	$54.60M	19.00	-$222.26M	-$1.86	N/A

In the previous week, Abeona Therapeutics had 11 more articles in the media than Immatics. MarketBeat recorded 15 mentions for Abeona Therapeutics and 4 mentions for Immatics. Abeona Therapeutics' average media sentiment score of 0.29 beat Immatics' score of 0.02 indicating that Abeona Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immatics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Abeona Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Abeona Therapeutics' return on equity of -41.69% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-41.69%	-30.36%
Immatics	-495.71%	-47.41%	-39.45%

Abeona Therapeutics has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Immatics has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

Summary

Abeona Therapeutics beats Immatics on 12 of the 16 factors compared between the two stocks.

How does Abeona Therapeutics compare to Vor Biopharma?

Abeona Therapeutics (NASDAQ:ABEO) and Vor Biopharma (NASDAQ:VOR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Abeona Therapeutics has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market.

Abeona Therapeutics has higher revenue and earnings than Vor Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	49.42	$71.18M	-$1.09	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by company insiders. Comparatively, 0.3% of Vor Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Abeona Therapeutics had 7 more articles in the media than Vor Biopharma. MarketBeat recorded 15 mentions for Abeona Therapeutics and 8 mentions for Vor Biopharma. Abeona Therapeutics' average media sentiment score of 0.29 beat Vor Biopharma's score of 0.21 indicating that Abeona Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vor Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vor Biopharma's return on equity of 0.00% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-41.69%	-30.36%
Vor Biopharma	N/A	N/A	N/A

Abeona Therapeutics presently has a consensus price target of $21.00, indicating a potential upside of 317.50%. Vor Biopharma has a consensus price target of $41.71, indicating a potential upside of 123.19%. Given Abeona Therapeutics' higher possible upside, research analysts clearly believe Abeona Therapeutics is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.90

Summary

Vor Biopharma beats Abeona Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Abeona Therapeutics compare to MannKind?

MannKind (NASDAQ:MNKD) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Abeona Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of 0.00% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-11.08%	N/A	-6.31%
Abeona Therapeutics	N/A	-41.69%	-30.36%

MannKind has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

49.6% of MannKind shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 2.6% of MannKind shares are owned by company insiders. Comparatively, 7.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Abeona Therapeutics had 7 more articles in the media than MannKind. MarketBeat recorded 15 mentions for Abeona Therapeutics and 8 mentions for MannKind. MannKind's average media sentiment score of 0.41 beat Abeona Therapeutics' score of 0.29 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abeona Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MannKind presently has a consensus target price of $8.34, indicating a potential upside of 119.57%. Abeona Therapeutics has a consensus target price of $21.00, indicating a potential upside of 317.50%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Abeona Therapeutics has lower revenue, but higher earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.50	$5.86M	-$0.13	N/A
Abeona Therapeutics	$5.82M	49.42	$71.18M	-$1.09	N/A

Summary

Abeona Therapeutics beats MannKind on 10 of the 16 factors compared between the two stocks.

Get Abeona Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABEO vs. The Competition

Export

Metric	Abeona Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$287.64M	$3.85B	$7.14B	$13.26B
Dividend Yield	N/A	3.65%	2.53%	17.32%
P/E Ratio	-4.69	7.65	214.28	21.57
Price / Sales	50.20	1,306.59	613.14	93.08
Price / Cash	N/A	39.04	27.22	34.70
Price / Book	1.74	17.06	11.23	6.40
Net Income	$71.18M	-$23.20M	$3.49B	$381.07M
7 Day Performance	-3.40%	-2.60%	-1.68%	-0.65%
1 Month Performance	-14.83%	-10.22%	-5.97%	-4.51%
1 Year Performance	-5.55%	19.55%	8.11%	1.82%

Abeona Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABEO Abeona Therapeutics	3.0047 of 5 stars	$5.11 +1.6%	$21.00 +311.0%	-7.0%	$287.64M	$5.82M	N/A	226
TRAX First Tracks Biotherapeutics	3.1155 of 5 stars	$36.65 +6.5%	$66.55 +81.6%	N/A	$1.23B	N/A	N/A	104	Positive News
REPL Replimune Group	1.4494 of 5 stars	$12.56 +1.6%	$12.00 -4.5%	+176.3%	$1.16B	N/A	N/A	465	Analyst Forecast
IMTX Immatics	3.4144 of 5 stars	$8.50 +1.6%	$20.60 +142.4%	-19.3%	$1.14B	$54.60M	N/A	704	High Trading Volume
VOR Vor Biopharma	1.9129 of 5 stars	$18.31 -1.1%	$41.71 +127.8%	-50.1%	$1.10B	N/A	N/A	76

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABEO) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abeona Therapeutics (ABEO) Competitors

ABEO vs. TRAX, REPL, IMTX, VOR, and MNKD

How does Abeona Therapeutics compare to First Tracks Biotherapeutics?

Summary

How does Abeona Therapeutics compare to Replimune Group?

Summary

How does Abeona Therapeutics compare to Immatics?

Summary

How does Abeona Therapeutics compare to Vor Biopharma?

Summary

How does Abeona Therapeutics compare to MannKind?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abeona Therapeutics (ABEO) Competitors

ABEO vs. TRAX, REPL, IMTX, VOR, and MNKD

How does Abeona Therapeutics compare to First Tracks Biotherapeutics?

Does the media favor ABEO or TRAX?

Is ABEO or TRAX more profitable?

Do analysts prefer ABEO or TRAX?

Do institutionals & insiders hold more shares of ABEO or TRAX?

Which has preferable earnings & valuation, ABEO or TRAX?

Summary

How does Abeona Therapeutics compare to Replimune Group?

Which has stronger valuation and earnings, ABEO or REPL?

Do analysts recommend ABEO or REPL?

Does the media favor ABEO or REPL?

Which has more volatility & risk, ABEO or REPL?

Is ABEO or REPL more profitable?

Do institutionals and insiders hold more shares of ABEO or REPL?

Summary

How does Abeona Therapeutics compare to Immatics?

Do insiders and institutionals hold more shares of ABEO or IMTX?

Do analysts prefer ABEO or IMTX?

Which has higher valuation and earnings, ABEO or IMTX?

Does the media refer more to ABEO or IMTX?

Is ABEO or IMTX more profitable?

Which has more risk & volatility, ABEO or IMTX?

Summary

How does Abeona Therapeutics compare to Vor Biopharma?

Which has more volatility and risk, ABEO or VOR?

Which has stronger earnings & valuation, ABEO or VOR?

Do institutionals & insiders hold more shares of ABEO or VOR?

Does the media refer more to ABEO or VOR?

Is ABEO or VOR more profitable?

Do analysts recommend ABEO or VOR?

Summary

How does Abeona Therapeutics compare to MannKind?

Is MNKD or ABEO more profitable?

Which has more risk and volatility, MNKD or ABEO?

Do insiders & institutionals hold more shares of MNKD or ABEO?

Does the media prefer MNKD or ABEO?

Do analysts rate MNKD or ABEO?

Which has higher valuation and earnings, MNKD or ABEO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools